Close

Biogen (BIIB), Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab

May 1, 2018 7:36 AM EDT Send to a Friend
Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login